Therapeutic
Solutions International Files Patent on Clinical Data Demonstrating
Reduction of Inflammatory Cytokines Using
NanoStilbeneTM
Oceanside, CA --
September 25, 2018 -- InvestosHub
NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today
filing of a patent covering novel clinical data using its
NanoStilbeneTM formulation to reduce
inflammatory cytokine production in cancer patients.
It is known that
these hormone-like substances, called cytokines, often reduce the
efficacy of immunotherapy. The Company believes that by reducing
inflammatory cytokines, administration of NanoStilbene may be used
to increase the efficacy of multibillion dollar a year cancer
immunotherapy drugs such as Herceptin.
"The data in the
patent filed today is highly applicable to the major obstacle of
cancer immunotherapy, which is, the chronic inflammatory
state in advanced
cancer patients," said Dr. James
Veltmeyer, Chief Medical Officer of Therapeutic Solutions
International. "As a physician who has personally seen the promise
of Immunotherapy, it is my personal mission to ensure that we
increase efficacy and decrease the toxicity of immunotherapy using
practical and simple to implement methods such as
NanoStilbene."
Immunotherapy is a
new type of cancer therapy that uses the immune system to
selectively seek and destroy tumor cells. In contrast to
chemotherapy or radiation therapy, immunotherapy teaches the immune
system to not only kill cancer but to "learn" from its encounters
and effectively fight recurrence and metastasis.
"The studies, which
were conducted in advanced cancer patients, demonstrated that daily
administration of 10ml of NanoStilbene resulted
in the reduction of TNF-alpha, CRP, and IL-6, all proteins
associated with chronic inflammation. One of the most
advanced immunotherapies is the use of CAR-T cells, whose
dose-limiting toxicity is associated with the production of
inflammatory cytokines. The data filed in the patent suggest the
possibility of using NanoStilbene to reduce side effects
of this
type of immunotherapy"
said
Timothy Dixon, President, and CEO of TSOI. "These data, which
will be formally published in the peer-reviewed literature, we
believe, strongly support the implementation of NanoStilbene
in
patients with advanced cancer."
About Therapeutic
Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION